Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16777
Title: A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant
Austin Authors: Davis, Ian D;Quirk, Juliet;Morris, Leone;Seddon, Lauren;Tai, Tsin Yee;Whitty, Genevieve;Cavicchiolo, Tina;Ebert, Lisa;Jackson, Heather;Browning, Judy;MacGregor, Duncan;Wittke, Frederick;Winkels, Gregor;Alex, Regina;Miloradovic, Lena;Maraskovsky, Eugene;Chen, Weisan;Cebon, Jonathan S 
Affiliation: Ludwig Institute for Cancer Research, Victoria, Australia
Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
Monash University Eastern Health Clinical School, Box Hill, Victoria, Australia
Eastern Health, Victoria, Australia
Department of Anatomical Pathology, Austin Health, Heidelberg, Victoria, Australia
Miltenyi Biotec, Germany
CSL Limited, Melbourne, Victoria, Australia
School of Cancer Medicine, La Trobe University, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Issue Date: Mar-2017
metadata.dc.date: 2017-02-10
Publication information: Immunotherapy 2017; 9(3): 249-259
Abstract: Pilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX™ adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses. PATIENTS & METHODS: Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS®plus, with initial depletion of CD1c+ B cells followed by positive selection of CD1c+ PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals. RESULTS: The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells did not correlate with outcomes. One patient had a long lasting complete remission. CONCLUSION: This method was feasible and safe but was minimally immunogenic.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16777
DOI: 10.2217/imt-2016-0132
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/28183192
Type: Journal Article
Subjects: ISCOMATRIX™ adjuvant
NY-ESO-1
Antigens
Clinical trial
Dendritic cells
Type of Clinical Study or Trial: Clinical Trial
Appears in Collections:Journal articles

Show full item record

Page view(s)

2
checked on Dec 1, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.